Page 54 - Toksoplazmoz Tanı ve Tedavi Uzlaşı Raporu

Toksoplazmoz Tanı ve Tedavi Uzlaşı Raporu

65. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, et al. Safe 76. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg
interruption of maintenance therapy against previous infection with MA, et al. Primary care guidelines for the management of persons in-
four common HIV-associated opportunistic pathogens during potent fected with HIV: 2013 update by the HIV medicine association of the
antiretroviral therapy. Ann Intern Med 2002;137:239-50. https://doi. Infectious Diseases Society of America. Clin Infect Dis 2014;58(1):e1-34.
org/10.7326/0003-4819-137-4-200208200-00008 https://doi.org/10.1093/cid/cit665
66. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in 77. Bozzette SA, Finkelstein DM, Spector SA, Frame P, Powderly WG, He W, et
HIV-1-infected persons after initiation of highly active antiretroviral ther- al. A randomized trial of three antipneumocystis agents in patients with
apy. Ann Intern Med 2000;133:447-54. https://doi.org/10.7326/0003- advanced human immunodeficiency virus infection. NIAID AIDS Clin-
4819-133-6-200009190-00013 ical Trials Group. N Engl J Med 1995 Mar 16;332(11):693-9. https://doi.
67. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. org/10.1056/NEJM199503163321101
Immune restoration disease after the treatment of immunodeficient 78. Schneider MME, Hoepelman AIM, Schattenkerk JKME, Nielsen TL, van
HIV-infected patients with highly active antiretroviral therapy. HIV Med der Graaf Y, Frissen JPHJ, et al. A controlled trial of aerosolized pentami-
2000;1:107-15. https://doi.org/10.1046/j.1468-1293.2000.00012.x dine or trimethoprim-sulfamethoxazole as primary prophylaxis against
68. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar Pneumocystis carinii pneumonia in patients with human immunode-
RL, Musher DM, et al. Immune reconstitution inflammatory syndrome: ficiency virus infection. The Dutch AIDS Treatment Group. N Eng J Med
Emergence of a unique syndrome during highly active antiretroviral 1992;327:1836-41. https://doi.org/10.1056/NEJM199212243272603
therapy. Medicine 2002;81:213-27. https://doi.org/10.1097/00005792- 79. Antinori A, Murri R, Ammassari A, de Luca A, Linzalone A, Cingolani A,
200205000-00005 et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimeth-
69. Michelet C, Arvieux C, François C, Besnier JM, Rogez JP, Breux JP, et al. amine for primary prophylaxis of Pneumocystis carinii pneumonia
Opportunistic infections occurring during highly active antiretrovi- and toxoplasmic encephalitis. AIDS (London, England) 1995;9:1343-50.
ral treatment. AIDS (London, England) 1998;12:1815-22. https://doi. https://doi.org/10.1097/00002030-199512000-00007
org/10.1097/00002030-199814000-00013 80. Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylac-
70. Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution tic treatments against Pneumocystis carinii pneumonia and toxoplas-
in HIV-infected patients. Clin Infect Dis 2004;38(8):1159-66. https://doi. ma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr
org/10.1086/383034 Hum Retrovirol 1997;15(2):104-14. https://doi.org/10.1097/00042560-
199706010-00002
71. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflamma-
tory syndrome: more answers, more questions. J Antimicrob Chemother 81. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infec-
2006;57(2):167-70. https://doi.org/10.1093/jac/dki444 tions in patients with HIV infection. Ann Intern Med 1994;120(11):932-44.
https://doi.org/10.7326/0003-4819-120-11-199406010-00006
72. Lawn SD. Immune reconstitution disease associated with parasitic infec-
tions following initiation of antiretroviral therapy. Curr Opin Infect Dis 82. Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary
2007;20(5):482-8. https://doi.org/10.1097/QCO.0b013e3282a6463d prophylaxis in HIV-1-infected patients at high risk of toxoplasma enceph-
alitis. Swiss HIV Cohort Study. Lancet (London, England) 2000;355:2217-
73. Tremont-Lukats IW, Garciarena P, Juarbe R, El-Abassi RN. The im- 8. https://doi.org/10.1016/S0140-6736(00)02407-7
mune inflammatory reconstitution syndrome and central nervous
system toxoplasmosis. Ann Intern Med 2009;150(9):656-7. https://doi. 83. Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, D’Arminio Monforte
org/10.7326/0003-4819-150-9-200905050-00025 A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii
pneumonia and toxoplasmic encephalitis in human immunodeficiency
74. Martin-Blondel G, Alvarez M, Delobel P, Uro-Coste E, Cuzin L, Cuvin- virus type I-infected patients: the changes in opportunistic prophylaxis
ciuc V, et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: A study. J Infect Dis 2000;181:1635-42. https://doi.org/10.1086/315471
case series and review of the literature. J Neurol Neurosurg Psychiatry
2011;82(6):691-3. https://doi.org/10.1136/jnnp.2009.199919
75. Zolopa AR, Andersen J, Komarow L, Sanne I, Sanchez A, Hogg E, et al. Ear-
ly antiretroviral therapy reduces AIDS progression/death in individuals
with acute opportunistic infections: A multicenter randomized strategy
trial. PloS One 2009;4. https://doi.org/10.1371/journal.pone.0005575

45